2023 World Conference on Lung Cancer (Posters)-EP12.01. The Contribution of Compound EGFR Mutations and Other Co-mutations to Efficacy of EGFR TKI in Lung Adenocarcinoma

EP12.01. The Contribution of Compound EGFR Mutations and Other Co-mutations to Efficacy of EGFR TKI in Lung Adenocarcinoma - PDF(Slides)

Back to course

Pdf Summary

This study aimed to investigate the contribution of compound EGFR mutations and other co-mutations to the efficacy of EGFR-tyrosine kinase inhibitor (TKI) treatment in EGFR mutant lung adenocarcinoma. The researchers conducted a single-center retrospective study on treatment-naïve patients with EGFR mutant lung adenocarcinoma at a tertiary referral hospital. The patients' tumor tissues were profiled and sequenced using the TruSight Oncology 500 panel and Illumina NextSeq 550 Dx.<br /><br />The study included a total of 76 patients, with 28 having the EGFR-L858R mutation, 41 with the EGFR-19 Del mutation, and 7 with uncommon mutations. The majority of the patients were female and never smokers. The researchers found different EGFR mutation types among the patients, with EGFR-19 Del being the most common subtype.<br /><br />They also examined the presence of co-occurring driver mutations and found that TP53 and HER2 were the most frequent mutations in both EGFR-L858R and EGFR-19 Del patients. The presence of any co-mutation was associated with a shorter progression-free survival compared to cases with only EGFR mutation.<br /><br />Based on their findings, the researchers suggested that molecular subgrouping and detection of co-driver mutations using NGS-based analysis are important in the treatment of EGFR mutant lung adenocarcinoma. They also emphasized the need for further research to understand the impact of specific co-mutations on treatment response.<br /><br />In summary, this study highlighted the importance of compound EGFR mutations and other co-mutations in the efficacy of EGFR-TKI treatment in EGFR mutant lung adenocarcinoma. The findings emphasized the need for personalized treatment approaches based on molecular subgrouping and the detection of co-driver mutations.

Asset Subtitle

Se Hyun Kwak

Meta Tag

Speaker Se Hyun Kwak

Topic Metastatic NSCLC: Targeted Therapy - EGFR/HER2

Keywords

compound EGFR mutations

co-mutations

EGFR-tyrosine kinase inhibitor

EGFR mutant lung adenocarcinoma

retrospective study

treatment-naïve patients

EGFR-L858R mutation

EGFR-19 Del mutation

progression-free survival

molecular subgrouping